AKT1 and neoplasm: Several mechanisms contribute to acquired refractoriness to sorafenib, including crosstalk between the PI3K/Akt and JAK-STAT pathways, activation of hypoxia-inducible pathways, epithelial–mesenchymal transition, and enrichment of tumor-initiating cell population [13].